MedTrace Logo

Artoss Prospective Spine Registry Outcomes

NCT04439032 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2025-02-12

No results posted yet for this study

Summary

This prospective registry was designed as an observational study to ascertain how commercially available NanoBone Bone Graft is being used by surgeons performing spinal fusion as well as determining relevant patient outcomes.

Conditions

  • Spinal Fusion

Interventions

OTHER

NanoBone Bone Graft Substitute

Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.

Sponsors & Collaborators

  • Artoss Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Cassidy, PhD · Artoss Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-03
Primary Completion
2024-10-31
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04439032 on ClinicalTrials.gov